Osteoclast Activation and Inflammatory Bone Diseases: Focusing on Receptors in Osteoclasts

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2025 Mar 10

PMID 40059949

Authors

Weijie Zhao

Ji Li

Tian Su

Chuanling Wang

Yonghua Fu

Changjia Li

Pengbing Hua

Xuelong Liang

Yongjun Zhu

Hongwang Cui

Affiliations

Soon will be listed here.

Abstract

Bone homeostasis depends on the balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. An increasing number of studies have revealed that under inflammatory conditions, osteoclast overactivation is responsible for bone loss in relevant bone diseases. Multiple signaling pathways such as receptor activator of nuclear factor-kappa B ligand (RANKL) signaling are involved in osteoclast activation. These signaling pathways rely on various receptors expressed on the surface of osteoclast progenitor cells (OPCs) or osteoclasts, which are activated by their corresponding ligands and subsequently trigger intracellular signaling. Targeting of these receptors may exert an inhibitory effect on osteoclast activation and inflammatory bone diseases. In this review, we discuss osteoclast activation and receptors involved in this process. The role of these receptors in relevant bone diseases has also been discussed.

References

Zhang Y, Liang J, Liu P, Wang Q, Liu L, Zhao H . The RANK/RANKL/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies. Front Endocrinol (Lausanne). 2023; 13:1063815. PMC: 9800780. DOI: 10.3389/fendo.2022.1063815. View

Takeuchi O, Akira S . Pattern recognition receptors and inflammation. Cell. 2010; 140(6):805-20. DOI: 10.1016/j.cell.2010.01.022. View

Rothe M, Sarma V, Dixit V, Goeddel D . TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science. 1995; 269(5229):1424-7. DOI: 10.1126/science.7544915. View

He S, Liang Y, Shao F, Wang X . Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. Proc Natl Acad Sci U S A. 2011; 108(50):20054-9. PMC: 3250173. DOI: 10.1073/pnas.1116302108. View

Dai X, Ryan G, Hapel A, Dominguez M, Russell R, Kapp S . Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood. 2002; 99(1):111-20. DOI: 10.1182/blood.v99.1.111. View

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

Grevers L, de Vries T, Everts V, Verbeek J, van den Berg W, van Lent P . Immune complex-induced inhibition of osteoclastogenesis is mediated via activating but not inhibitory Fcγ receptors on myeloid precursor cells. Ann Rheum Dis. 2012; 72(2):278-85. DOI: 10.1136/annrheumdis-2012-201568. View

Henning P, Kassem A, Westerlund A, Lundberg P, Engdahl C, Lionikaite V . Toll-like receptor-2 induced inflammation causes local bone formation and activates canonical Wnt signaling. Front Immunol. 2024; 15:1383113. PMC: 11026618. DOI: 10.3389/fimmu.2024.1383113. View

Liu D, Liu W, Jiang L, Dong S, Ma W, Wang S . Silencing of TLR7 protects against lipopolysaccharide-induced chondrocyte apoptosis and injury by blocking the p21-mediated JAK2/STAT3 pathway. Am J Transl Res. 2022; 13(12):13555-13566. PMC: 8748165. View

10.

Oddie G, Schenk G, Angel N, Walsh N, Guddat L, De Jersey J . Structure, function, and regulation of tartrate-resistant acid phosphatase. Bone. 2000; 27(5):575-84. DOI: 10.1016/s8756-3282(00)00368-9. View

11.

Barrow A, Raynal N, Andersen T, Slatter D, Bihan D, Pugh N . OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest. 2011; 121(9):3505-16. PMC: 3163954. DOI: 10.1172/JCI45913. View

12.

Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H . Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002; 3(6):889-901. DOI: 10.1016/s1534-5807(02)00369-6. View

13.

Idress M, Milne B, Thompson G, Trembleau L, Jaspars M, Houssen W . Structure-Based Design, Synthesis and Bioactivity of a New Anti-TNFα Cyclopeptide. Molecules. 2020; 25(4). PMC: 7071015. DOI: 10.3390/molecules25040922. View

14.

Patin E, Willcocks S, Orr S, Ward T, Lang R, Schaible U . Mincle-mediated anti-inflammatory IL-10 response counter-regulates IL-12 in vitro. Innate Immun. 2016; 22(3):181-5. PMC: 4826952. DOI: 10.1177/1753425916636671. View

15.

Shi V, Morgan E . Estrogen and estrogen receptors mediate the mechanobiology of bone disease and repair. Bone. 2024; 188:117220. PMC: 11392539. DOI: 10.1016/j.bone.2024.117220. View

16.

Steinle J . Role of HMGB1 signaling in the inflammatory process in diabetic retinopathy. Cell Signal. 2020; 73:109687. PMC: 7387203. DOI: 10.1016/j.cellsig.2020.109687. View

17.

Herman S, Muller R, Kronke G, Zwerina J, Redlich K, Hueber A . Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum. 2008; 58(10):3041-50. DOI: 10.1002/art.23943. View

18.

Jiang T, Xia T, Qiao F, Wang N, Jiang Y, Xin H . Role and Regulation of Transcription Factors in Osteoclastogenesis. Int J Mol Sci. 2023; 24(22). PMC: 10671247. DOI: 10.3390/ijms242216175. View

19.

Park J, Lee N, Lee S . Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation. Mol Cells. 2017; 40(10):706-713. PMC: 5682248. DOI: 10.14348/molcells.2017.0225. View

20.

Davis H, Essex A, Valdez S, Deosthale P, Aref M, Allen M . Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice. Bone. 2019; 124:89-102. PMC: 6543548. DOI: 10.1016/j.bone.2019.04.012. View